HM 12525A

Drug Profile

HM 12525A

Alternative Names: GLP-1/glucagon-agonist; Glucagon-like-peptides/glucagon; Glucagon/GLP-1-agonist; HM12525A; JNJ 5111; JNJ-64565111; LAPS GLP/GCG; LAPS- GLP/Glucagon; LAPS-GCG/GLP-1; LAPS-GLP-1/GCG; LAPS-OXM; Oxyntomodulin immunoglobulin conjugate

Latest Information Update: 09 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hanmi Pharmaceutical
  • Developer Hanmi Pharmaceutical; Janssen Pharmaceuticals
  • Class Antihyperglycaemics; Drug conjugates; Gastrointestinal hormones; Glucagon-like peptides; Immunoconjugates; Obesity therapies
  • Mechanism of Action Glucagon like peptide 1 receptor agonists; Glucagon receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Obesity
  • Phase I Type 2 diabetes mellitus

Most Recent Events

  • 26 Mar 2018 Phase-II clinical trials in Obesity in USA (SC) (NCT03486392)
  • 04 Aug 2017 Janssen plans a phase I trial for Type-2 diabetes mellitus in USA (NCT03235219)
  • 01 Aug 2017 Phase-Ib clinical trials in Type-2 diabetes mellitus (In adults, In the elderly) in USA (SC) (NCT03235219)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top